Details of the Drug

General Information of Drug (ID: DM5T6US)

Drug Name
Estrone
Synonyms
Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Menopausal and postmenopausal disorder GA30 Approved [2]
Therapeutic Class
Antimenopausal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 270.4
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The absorption of drug is 43% []
Half-life
The concentration or amount of drug in body reduced by one-half in 19 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C18H22O2
IUPAC Name
(8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
InChI
InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
InChIKey
DNXHEGUUPJUMQT-CBZIJGRNSA-N
Cross-matching ID
PubChem CID
5870
ChEBI ID
CHEBI:17263
CAS Number
53-16-7
DrugBank ID
DB00655
TTD ID
D00ZFP
VARIDT ID
DR00494
INTEDE ID
DR0648
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Agonist [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [9]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [12]
Estradiol 17-beta-dehydrogenase 2 (HSD17B2) DEBMFZ8 DHB2_HUMAN Substrate [13]
Keto-steroid reductase (HSD17B7) DEDMWFX DHB7_HUMAN Substrate [13]
Farnesol dehydrogenase (AKR1B15) DER0XCH AK1BF_HUMAN Substrate [14]
Lauric acid omega-hydroxylase (CYP4A11) DE2XQGW CP4AB_HUMAN Substrate [12]
Peroxisomal multifunctional enzyme 2 (HSD17B4) DEJHG19 DHB4_HUMAN Substrate [13]
Ketoacyl-CoA reductase (HSD17B12) DE915QP DHB12_HUMAN Substrate [15]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Biotransformations [13]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2) OT3K7HY5 DHB2_HUMAN Biotransformations [13]
3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 (HSD17B7) OTV7VOV3 DHB7_HUMAN Biotransformations [13]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Regulation of Drug Effects [16]
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Biotransformations [17]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Gene/Protein Processing [18]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Biotransformations [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [5]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [19]
Carbonic anhydrase 12 (CA12) OT6WNFU8 CAH12_HUMAN Gene/Protein Processing [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 7.75E-01 -1.76E-01 -6.23E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 3.97E-02 -1.72E-01 -9.29E-01
Peroxisomal multifunctional enzyme 2 (HSD17B4) DME HSD17B4 7.65E-01 -2.57E-02 -1.57E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 9.96E-01 -7.53E-02 -5.68E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Keto-steroid reductase (HSD17B7) DME HSD17B7 1.13E-01 -1.66E-01 -4.75E-01
Estradiol 17-beta-dehydrogenase 2 (HSD17B2) DME HSD17B2 9.57E-01 -3.67E-03 -2.48E-02
Cytochrome P450 1B1 (CYP1B1) DME CYP1B1 6.91E-03 2.71E-01 1.34E+00
Ketoacyl-CoA reductase (HSD17B12) DME HSD17B12 7.76E-01 -1.30E-01 -2.17E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.01E-01 -1.01E-02 -6.05E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.09E-01 -9.26E-02 -3.68E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Lauric acid omega-hydroxylase (CYP4A11) DME CYP4A11 7.58E-02 -1.17E-01 -8.85E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Estrone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Estrone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Arn-509 DMT81LZ Moderate Increased metabolism of Estrone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Estrone caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Estrone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [21]
Posaconazole DMUL5EW Moderate Decreased metabolism of Estrone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [23]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Estrone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Estrone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Estrone caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [21]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Estrone caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Tucatinib DMBESUA Moderate Decreased metabolism of Estrone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Atorvastatin DMF28YC Minor Decreased metabolism of Estrone caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [28]
Mifepristone DMGZQEF Moderate Decreased metabolism of Estrone caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [24]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Estrone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [29]
Aprepitant DM053KT Moderate Decreased metabolism of Estrone caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [30]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Estrone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Primidone DM0WX6I Moderate Increased metabolism of Estrone caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Felbamate DM1V5ZS Moderate Increased metabolism of Estrone caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Cenobamate DM8KLU9 Moderate Increased metabolism of Estrone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Estrone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Rufinamide DMWE60C Moderate Increased metabolism of Estrone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Phenobarbital DMXZOCG Moderate Increased metabolism of Estrone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Estrone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Dantrolene DM1D8XY Major Increased risk of hepatotoxicity by the combination of Estrone and Dantrolene. Fever [MG26] [33]
Tazemetostat DMWP1BH Moderate Increased metabolism of Estrone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [34]
Itraconazole DMCR1MV Moderate Decreased metabolism of Estrone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Miconazole DMPMYE8 Moderate Decreased metabolism of Estrone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Estrone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
ABT-450 DMFW860 Major Decreased metabolism of Estrone caused by ABT-450 mediated inhibition of UGT. Hepatitis virus infection [1E50-1E51] [35]
Rifampin DMA8J1G Moderate Increased metabolism of Estrone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [21]
Rifapentine DMCHV4I Moderate Increased metabolism of Estrone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [20]
Delavirdine DM3NF5G Minor Decreased metabolism of Estrone caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Tipranavir DM8HJX6 Moderate Increased risk of skin rash by the combination of Estrone and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [37]
Saquinavir DMG814N Moderate Decreased metabolism of Estrone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Conivaptan DM1V329 Moderate Decreased metabolism of Estrone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Amobarbital DM0GQ8N Moderate Increased metabolism of Estrone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [21]
Melatonin DMKWFBT Minor Decreased metabolism of Estrone caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [24]
Brigatinib DM7W94S Moderate Increased metabolism of Estrone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
PF-06463922 DMKM7EW Moderate Increased metabolism of Estrone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [20]
Selpercatinib DMZR15V Moderate Decreased metabolism of Estrone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [41]
IPI-145 DMWA24P Moderate Decreased metabolism of Estrone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [42]
Vemurafenib DM62UG5 Moderate Increased metabolism of Estrone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Estrone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Exjade DMHPRWG Moderate Decreased metabolism of Estrone caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [43]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Estrone and Carfilzomib. Multiple myeloma [2A83] [24]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Estrone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Nilotinib DM7HXWT Moderate Decreased metabolism of Estrone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [44]
Dasatinib DMJV2EK Moderate Decreased metabolism of Estrone caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Modafinil DMYILBE Minor Increased metabolism of Estrone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [46]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Estrone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [47]
Abametapir DM2RX0I Moderate Decreased metabolism of Estrone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [48]
Lefamulin DME6G97 Moderate Decreased metabolism of Estrone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [49]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Estrone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [50]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Estrone and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [51]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Estrone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [52]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Estrone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [32]
Larotrectinib DM26CQR Moderate Decreased metabolism of Estrone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Armodafinil DMGB035 Minor Increased metabolism of Estrone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [46]
Warfarin DMJYCVW Moderate Antagonize the effect of Estrone when combined with Warfarin. Supraventricular tachyarrhythmia [BC81] [53]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Estrone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [54]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Estrone and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [51]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Estrone and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [51]
⏷ Show the Full List of 61 DDI Information of This Drug

References

1 Estrone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2818).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
5 P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
6 Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
7 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
8 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
9 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
10 A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63.
11 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
12 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
13 Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
14 Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
15 Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006 Feb;20(2):437-43.
16 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
17 The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm Res. 1992 Apr;9(4):497-503. doi: 10.1023/a:1015840329786.
18 Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
19 Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci. 2006;9(1):133-9.
20 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
21 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
22 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
23 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
26 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
28 Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
29 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
30 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
31 Adson DE, Kotlyar M "A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report." J Clin Psychopharmacol 21 (2001): 618-9. [PMID: 11763013]
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Product Information. Dantrium (dantrolene). Procter and Gamble Pharmaceutic, Cincinnati, OH.
34 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
35 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
36 Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther 61 (1997): 531-43. [PMID: 9164415]
37 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
38 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
39 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
40 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
41 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
42 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
43 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
45 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
46 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
47 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
48 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
51 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
53 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
54 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.